Mostrar el registro sencillo del ítem
Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate
dc.contributor.author | Sisteré-Oró, Marta | |
dc.contributor.author | Pedersen, Gabriel K. | |
dc.contributor.author | Córdoba, Lorena | |
dc.contributor.author | López-Serrano, Sergi | |
dc.contributor.author | Christensen, Dennis | |
dc.contributor.author | Darji, Ayub | |
dc.contributor.other | Producció Animal | ca |
dc.date.accessioned | 2020-07-06T10:54:08Z | |
dc.date.available | 2020-07-06T10:54:08Z | |
dc.date.issued | 2020-04-20 | |
dc.identifier.citation | Sisteré-Oró, Marta, Gabriel K. Pedersen, Lorena Córdoba, Sergi López-Serrano, Dennis Christensen, and Ayub Darji. 2020. "Influenza NG-34 T Cell Conserved Epitope Adjuvanted With CAF01 As A Possible Influenza Vaccine Candidate". Veterinary Research 51 (1). doi:10.1186/s13567-020-00770-4. | ca |
dc.identifier.issn | 0928-4249 | ca |
dc.identifier.uri | http://hdl.handle.net/20.500.12327/866 | |
dc.description.abstract | Conserved epitopes are targets commonly researched to be part of universal vaccine candidates against influenza viruses (IV). These conserved epitopes need to be cross-protecting against distinct IV subtypes and to have a strong immunogenic potential. Nevertheless, subunit vaccines generally require a strong adjuvant to enhance their immunological effects. Herewith, we compare four different adjuvants differing in their immunological signatures that may enhance efficacy of a conserved hemagglutinin (HA)-epitope from IV, the NG-34, to define the most efficient combination of antigen/adjuvant to combat IV infections. Soluble NG-34 was mixed with adjuvants like aluminium hydroxide (AH) and AddaVax, known to induce Th2 and humoral responses; CAF01 which displays a biased Th1/Th17 profile and Diluvac Forte which augments the humoral response. Combinations were tested in different groups of mice which were subjected to immunological analyses. CAF01 + NG-34 induced a complete immune response with the highest IgG1, IgG2c titers and percentages of activated CD4 T cell promoting IFN-γ, IL-2 and TNF-α producing cells. Furthermore, in NG-34 stimulated mice splenocytes, cytokine levels of IFN-γ, IL-1β, IL-6, IL-10, IL-17 and TNF-α were also the highest in the CAF01 + NG-34 mouse group. This complete induced immune response covering the humoral and the cellular arms of the adaptive immunity promoted by CAF01 + NG-34 group suggests that CAF01 could be a good candidate as an adjuvant to combine with NG-34 for an efficacious vaccine against IV. However, more studies performed in IV hosts as well as studies with a challenge model are further required. | ca |
dc.format.extent | 11 | ca |
dc.language.iso | eng | ca |
dc.publisher | BMC | ca |
dc.relation.ispartof | Veterinary Research | ca |
dc.rights | Attribution 4.0 International | ca |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.title | Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate | ca |
dc.type | info:eu-repo/semantics/article | ca |
dc.description.version | info:eu-repo/semantics/publishedVersion | ca |
dc.rights.accessLevel | info:eu-repo/semantics/openAccess | |
dc.embargo.terms | cap | ca |
dc.relation.projectID | EC/H2020/730964/ES/European Vaccine Research and Development Infrastructure/TRANSVAC2 | ca |
dc.relation.projectID | MINECO/Programa estatal de I+D+I orientada a los retos de la sociedad/AGL2013-48923-C2-2-R/ES/Nuevas estrategias vacunales frente a enfermedades víricas ganaderas empleando pseudopartículas virales modificadas/ | ca |
dc.subject.udc | 619 | ca |
dc.identifier.doi | https://doi.org/10.1186/s13567-020-00770-4 | ca |
dc.contributor.group | Sanitat Animal | ca |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
ARTICLES CIENTÍFICS [2.510]